Login

u/pfelgueiras

r/biotech_stocks r/OTLK_Investors
OTLK - EFECTIVE NOV 01, 2026 - Blue Cross Blue Shield of NORTH DAKOTA includes LYTENAVA
▲ 11 r/OTLK_Investors

OTLK - EFECTIVE NOV 01, 2026 - Blue Cross Blue Shield of NORTH DAKOTA includes LYTENAVA

https://preview.redd.it/d4x68058mith1.png?width=844&format=png&auto=webp&s=3157c50adc1b952c7bd08e70db5f1cddbeb6c7a4

Retina Consultants of America (RCA), which is owned by Cencora, has an active presence and serves patients in North Dakota.

Blue Cross Blue Shield of North Dakota (BCBSND) has added Lytenava (bevacizumab-vikg) to its new Commercial prior authorization medical drug policies, effective November 1, 2026.

Key Details

  • Drug Name: Lytenava (bevacizumab-vikg).
  • Effective Date: November 1, 2026.
  • Policy Type: Commercial prior authorization medical drug policy.
  • Indication: Ophthalmic formulation approved for neovascular (wet) age-related macular degeneration (nAMD).
  • Contact Support: Provider Service is available at 800-368-2312, and Medicaid Expansion inquiries can reach 833-777-5779. Further policy display information can be checked directly via BCBSND Pharmacy Policies.

According to an official bulletin published on the BCBSND Healthcare News Portal, Blue Cross Blue Shield of North Dakota has formally designated Lytenava (bevacizumab-vikg) under its new Commercial prior authorization medical drug policies.

The policy update is explicitly scheduled to become effective on November 1, 2026. Providers can look up the complete clinical criteria on the insurer's policy portal on or after that effective date.

reddit.com
u/pfelgueiras — 11 days ago
▲ 11 r/OTLK_Investors+1 crossposts

OTLK - Blue Cross and Blue Shield of Minnesota, oldest and largest health plan in the state of Minnesota, founded in 1933.

Blue Cross and Blue Shield of Minnesota covers intravitreal injections of ophthalmic medications like Lytenava (bevacizumab-vikg) under its medical policies for retinal conditions, though explicit coverage terms depend on your specific health plan

Blue Cross and Blue Shield of Minnesota evaluates new-to-market FDA-approved drugs—such as bevacizumab-vikg (LYTENAVA)—under its standard clinical review framework. When a drug is newly approved by the FDA, it is typically designated as experimental or investigational by the health plan. 

This status remains in place until the Blue Cross Medical Pharmacy & Therapeutics Committee finishes its evaluation to dictate specific coverage and prior authorization guidelines.

Key Facts About the Drug Update

  • The Medication: LYTENAVA (bevacizumab-vikg) was approved by the FDA as the first dedicated ophthalmic formulation of bevacizumab designed specifically for intravitreal injection.
  • The Indication: It is indicated for treating neovascular (wet) age-related macular degeneration (nAMD).
  • Review Window: Blue Cross and Blue Shield of Minnesota generally reviews new FDA-approved medical benefit drugs within 6 months of their market release to establish updated medical policies.

Blue Cross and Blue Shield of Minnesota (BCBSMN) is the oldest and largest health plan in the state of Minnesota, founded in 1933. It is a non-profit organization headquartered in Eagan, Minnesota, serving over two million beneficiaries. As an independent licensee of the Blue Cross and Blue Shield Association, the company offers a broad national network of physicians and hospitals. 

reddit.com
u/oblkbirdo — 17 days ago
▲ 18 r/OTLK_Investors

OTLK - Added to S&P Global BMI Index.

Outlook Therapeutics, Inc. (NasdaqCM: OTLK) was officially added to the S&P Global BMI (Broad Market Index) on September 20, 2026.

Index Addition Overview

  • Action: Added to the S&P Global BMI Index
  • Effective Date: September 20, 2026
  • Exchange/Ticker: NasdaqCM: OTLK
  • Market Context: Reflects evolving float and capitalization criteria adjustments for the micro-cap biopharma.

SOURCE:

https://www.marketscreener.com/news/outlook-therapeutics-inc-nasdaqcm-otlk-added-to-s-p-global-bmi-index-ce785ad9df8efe25

u/pfelgueiras — 19 days ago
▲ 5 r/OTLK_Investors

OTLK - Open NEW Job Position for FINANCIAL PLANNING AND ANALYSIS MANAGER

https://preview.redd.it/ztcz6xl6qcqh1.png?width=936&format=png&auto=webp&s=b203e631fdd34536761795246d50f9af437cdb82

About the job:

ABOUT OUTLOOK THERAPEUTICS

Outlook Therapeutics (Nasdaq: OTLK) is a commercial-stage biopharmaceutical company redefining the standard of care in retinal disease. In the United States, our lead product has received FDA approval, making it the first and only FDA-approved ophthalmic formulation of its kind for the treatment of wet AMD, and we are preparing for US commercial launch.

Our lead product is also the first ophthalmic formulation of its kind to receive Marketing Authorization from the European Commission and the UK MHRA for the treatment of wet age-related macular degeneration (wet AMD), and has launched across Germany, Austria, and the UK.

Driven by the stories of the patients we serve, we are united with the vision-care community around a single goal: a future where everyone with retinal disease can envision a brighter world.

THE OPPORTUNITY

Reports To: Senior Director, Commercial FinanceLevel:

ManagerLocation: Remote (US-based)

Employment Type: Full-timeDirect

Reports: No

This is a rare ground-floor moment at a company hitting its commercial inflection point.

As a lean, fast-moving organization, we offer scope and ownership that larger companies can’t: your work is visible, your decisions matter, and you’ll help build the function rather than simply maintain it.

You’ll partner directly with senior leadership and see a clear line between what you do and patients gaining access to a new treatment option.

FP&A Manager, you will be a key finance business partner to Corporate G&A, Tech Ops, and Medical leaders, supporting the financial management and growth of Outlook Therapeutics during an active product launch — owning financial planning and analysis, expense management, management reporting, and the financial insights that drive strategic and operational decisions.

As

WHAT YOU'LL DO

•Financial Planning & Analysis

•Lead the annual budget, long-range plan, and quarterly forecast processes for Corporate G&A, Tech Ops, and Medical.

•Build and maintain financial models that give clear visibility into departmental spend, headcount, and product-level investment.

•Analyze variances and trends and deliver actionable insights and recommendations to management.

•Drive process improvements that increase forecasting efficiency and reporting quality, including supporting FP&A system implementation and maintenance.

•Support Board and investor activities and presentations.

•Expense Management & Reporting

•Consolidate and distribute monthly department reports of YTD operating expenses versus budget/forecast to department leaders.

•Partner with Accounting, HR, and departmental finance contacts to reconcile data and ensure consistency between actuals and forecasts.

•Track spending, headcount, and vendor commitments with functional leaders; surface variances and key cost drivers.

•Serve as a critical reviewer of material purchases, ensuring alignment with corporate goals and budget.

•Business Development Support

•Engage in qualitative discussions on key assumptions underlying potential M&A, licensing, and co-promote deals.

•Build financial models to determine deal value to Outlook Therapeutics and the potential partner.

•Present analysis to executive leadership to guide decision-making.

 

WHAT YOU'LL BRING

Required

•Bachelor's degree in Finance, Accounting, Economics, or a related field.

•5+ years of experience in FP&A or corporate finance demonstrating increasing responsibility.

•Proficiency in financial planning & analysis and ERP systems (e.g., NetSuite).

•Advanced Excel, PowerPoint, and financial modeling skills.

•Demonstrated experience partnering with senior business leaders and cross-functional teams.

Preferred

•MBA, CPA, or other relevant advanced degree/certification.

•Experience in the pharmaceutical, biotechnology, or healthcare industry strongly preferred.

•Experience scaling FP&A systems and processes through a product launch or rapid-growth phase.

•Strong working knowledge of US GAAP.

 

WHAT WE OFFER

•Competitive base salary, annual performance bonus, and equity — so you share in the value you help create

•Comprehensive health coverage: medical, dental, and vision

•401(k) with company match

•Generous paid time off and company holidays

•A high-trust, low-bureaucracy culture with direct access to leadership and real room to grow

•Mission-driven work that helps preserve sight for patients who are counting on it

 

COMPENSATION

In keeping with our commitment to pay transparency, the good-faith base salary range for this role is $110,000-$145,000, with an annual target bonus of 15%. This role is also eligible for a meaningful equity grant, reflecting the opportunity to build lasting value at a company at a commercial inflection point. Final compensation reflects experience, skills, and location.

OUR COMMITMENT

Outlook Therapeutics is an equal opportunity employer. We are committed to building an inclusive environment where every team member can do their best work, and we consider all qualified applicants without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, disability, veteran status, or any other characteristic protected by law.

Benefits found in job post

 401(k)

Requirements added by the job poster

• Bachelor's Degree

• 2+ years of work experience with NetSuite

• 5+ years of work experience with Financial Planning and Analysis (FP&A)

SOURCE:

LINKEDIN

reddit.com
u/pfelgueiras — 27 days ago
▲ 9 r/OTLK_Investors

OTLK - Speaking at the Alcura Summit, Jedd Comiskey, SVP, Head of Europe at Outlook Therapeutics,

The strongest sourcing partnerships contribute far more than product supply.

Speaking at the Alcura Summit, Jedd Comiskey, SVP, Head of Europe at Outlook Therapeutics, reflected on the value of bringing expertise together across multiple functions during a complex European launch.

His comments reinforce a key message from our latest article: sourcing providers are becoming strategic partners, helping sponsors manage regulatory complexity, supply risk and operational decision-making much earlier in the study lifecycle.

https://preview.redd.it/vj6jqc8wczoh1.png?width=936&format=png&auto=webp&s=a12ad1afef72dcb8f724410365d9d471dcbb7ce9

SOURCE:

Linkedin

reddit.com
u/pfelgueiras — 1 month ago
▲ 11 r/OTLK_Investors

OTLK - JOHN MAGLIOCCHETTI - NEW Senior Director, HCP Marketing

reddit.com
u/pfelgueiras — 1 month ago
▲ 18 r/OTLK_Investors

OTLK - CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in a Virtual Investor CEO Connect segment discussing the significance of the FDA approval of LYTENAVA and the Company’s plans for its U.S. commercial launch.

During the segment, Mr. Jahr discusses the potential of LYTENAVA to address the significant U.S. retina market by providing physicians with the only FDA-approved ophthalmic formulation of bevacizumab for wet AMD. He also discusses the Company’s potential to shift existing off-label use to LYTENAVA and its opportunity to achieve more than $500 million in annual U.S. sales by 2030.

The segment also highlights Outlook Therapeutics’ commercial readiness efforts ahead of its planned U.S. launch before the end of 2026, including manufacturing, distribution, market access, reimbursement, and physician education, as well as key learnings from the Company’s commercialization efforts in Europe.

“FDA approval of LYTENAVA marks an important transformation for Outlook Therapeutics as we move into our next phase as a commercial-stage company,” said Bob Jahr. “We believe LYTENAVA has the potential to make a meaningful impact for retina physicians and patients while addressing a significant market opportunity. We are focused on executing our U.S. launch strategy and building on the experience gained through our European commercialization efforts.”

The Virtual Investor CEO Connect segment is available to watch here.

SOURCE:

https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-ceo-bob-jahr-discusses-fda-approval-and

reddit.com
u/pfelgueiras — 1 month ago
▲ 14 r/OTLK_Investors

OTLK - INTERESTING POINT OF VIEW

Subject: Urgent Investor Inquiry: Public Awareness and Commercialization Strategy for LYTENAVA™

Dear Members of the Board and Executive Management Team, I am writing to you as a dedicated and long-term shareholder of Outlook Therapeutics.

While I congratulate the company on securing FDA approval for our licensed product—which offers a permanent solution for patients suffering from macular degeneration and comes with a valuable 12-year exclusivity period—I must voice serious concerns regarding the current post-approval trajectory and market communication.

We have closely followed your strategic steps, including building the launch team, transitioning the CFO, and securing a crucial distribution partnership with Cencora.

However, despite these major milestones, the stock price has sharply declined instead of rising. It is evident to the investment community that this is a direct result of heavy share dilution.

With an estimated $50M+ in cash reserves ahead of the official launch, the company is well-funded to advance its operations.

Yet, the current approach to communication makes it feel as though you are handling classified nuclear material rather than a life-changing, FDA-approved medical product.

The last public relations (PR) update was issued on August 27th, and the ongoing silence since then is deeply troubling.Why is there a complete lack of transparency regarding your day-to-day efforts to introduce this drug to the market?

Shareholders deserve to know about your promotional activities.

If you are conducting interviews with radio stations, meeting with foundations, engaging with medical associations, or presenting to physician groups, why are these updates not being shared? If you are not doing these things, the question becomes even more urgent: why are you not actively marketing this product?

Promoting this drug does not strictly require massive capital expenditure or expensive advertising campaigns.

You have an approved product in the United States, not a restricted item in a closed state like North Korea.

There are countless cost-effective ways to build public awareness and professional engagement through community outreach, medical advocacy, and public relations.What is being hidden from the investors?

I strongly urge the management to step up its public relations efforts, demonstrate the active commercialization of our asset, and start communicating transparently with the market to restore shareholder value.

I look forward to seeing proactive updates and a more robust public awareness strategy in the immediate future.

Sincerely, Shareholder, Outlook Therapeutics Inc.

SOURCE:

post on Stocktwist by digger01

reddit.com
u/pfelgueiras — 1 month ago
▲ 6 r/OTLK_Investors

OTLK - Open NEW Job Position for IT MANAGER (remote)

https://preview.redd.it/jcrgllufuhnh1.png?width=918&format=png&auto=webp&s=f72a2d0a12d2c7b0df3c1faf92842111e4f3a658

About the job

Under limited supervision and with significant independent judgment, the Manager, IT – Integrations and Automation leads the Integrations Team within Information Technology. This role is responsible for the design, delivery, support, governance, and continuous improvement of enterprise integrations and APIs, ensuring integration architecture, API management practices, integration frameworks, and delivery standards align with current operational needs and future business and technology strategy. The role advances modern integration engineering practices including API-first design, cloud-native integration patterns, event-driven architecture, DevSecOps, automation, resiliency, and observability. The role supports integrations with core insurance systems, including Guidewire, and other data and insurance marketplace providers. This leader also assesses enterprise automation opportunities and advances robotic process automation capabilities while coordinating appropriately with teams pursuing modern generative AI capabilities. This position is not responsible for enterprise AI strategy or AI enablement.

Essential Duties And Responsibilities

  • Leads the Integrations Team, including daily operations, work prioritization, resource planning, delivery oversight, production support, and continuous improvement of integration practices.
  • Establishes and maintains integration architecture direction, standards, patterns, and frameworks that support scalability, resiliency, security, maintainability, and alignment with future business and technology strategy.
  • Establishes and governs enterprise API management practices, including API lifecycle management, API Gateway standards, versioning, security, monitoring, developer enablement, and service reuse across the organization.
  • Oversees the design, development, testing, implementation, and support of integrations across enterprise applications, core insurance platforms, third-party providers, and digital channels.
  • Promotes modern software engineering and integration delivery practices including CI/CD, automated testing, code quality standards, DevSecOps, reusable integration frameworks, infrastructure automation, and continuous improvement of delivery processes.
  • Ensures integration solutions support core insurance systems, including Guidewire and Guidewire Cloud Platform (GWCP), and meet business, operational, data, security, and compliance requirements. Provides technical leadership for Guidewire Cloud integration patterns, Guidewire Cloud Integration Gateway connectivity, and integration modernization initiatives.
  • Maintains knowledge of insurance marketplace providers, solution capabilities, integration models, and vendor ecosystems to inform technology decisions and implementation approaches.
  • Partners with architecture, application development, infrastructure, security, data, business, and vendor teams to ensure integration solutions are strategically aligned, technically sound, and operationally sustainable.
  • Assesses enterprise automation needs and identifies opportunities to use robotic process automation to improve efficiency, reduce manual effort, strengthen controls, and enhance business outcomes.
  • Leads RPA planning, prioritization, implementation, governance, support, and value realization in coordination with business stakeholders and technology partners.
  • Coordinates with teams pursuing modern generative AI capabilities to ensure automation efforts are complementary, without owning enterprise AI strategy or AI enablement responsibilities.
  • Provides technical leadership and decision support for integration design choices, vendor evaluations, implementation plans, production issues, and long-term platform direction.
  • Ensures appropriate change management, testing, documentation, monitoring, incident response, audit support, and operational controls are in place for assigned systems and integrations.
  • Establishes integration observability, logging, tracing, monitoring, alerting, and resiliency standards to improve reliability, accelerate issue diagnosis, and reduce business disruption.
  • Develops, recommends, and implements operational plans, procedures, performance goals, and service expectations for the team.
  • Leads, coaches, and develops staff; prepares and conducts performance appraisals; and supports hiring, workforce planning, corrective action, recognition, and other employment-related activities in accordance with company policies.
  • Coordinates resources and activities to achieve project objectives.
  • Performs other duties as assigned.

Qualifications

The requirements listed below are representative of the knowledge, skills, abilities, education, and experience required to successfully perform the essential functions of this position.

Education and Experience

  • Bachelor’s degree in Computer Science, Information Systems, Engineering, or a related field required.
  • Previous experience leading technical teams, managing priorities, developing talent, and delivering results through others required.
  • Experience with integration architecture, API management platforms, API Gateway technologies, integration frameworks, middleware, event-driven architecture, cloud-native integration patterns, data movement, system connectivity, and production support practices required.
  • Experience with Guidewire Cloud Platform (GWCP), Guidewire Cloud Integration Gateway, InsuranceSuite Cloud integrations, or similar cloud-based core platform modernization initiatives preferred.
  • Experience assessing, implementing, or supporting robotic process automation solutions preferred.

Required Knowledge, Skills, And Abilities

  • Strong technical acumen, including demonstrated understanding of integration architecture, system interoperability, API management, API Gateway technologies, event-driven architecture, security considerations, and operational support models.
  • Ability to align technology decisions with business strategy, enterprise architecture direction, operational needs, and future-state capabilities.
  • Knowledge of insurance technology ecosystems, marketplace providers, and integrations supporting policy, billing, claims, customer, agent, data, and digital capabilities. Experience with Guidewire, Guidewire Cloud and Guidewire Cloud Integration Gateway preferred.
  • Ability to evaluate vendor solutions and integration approaches for business fit, technical alignment, implementation complexity, operational impact, and long-term sustainability.
  • Ability to identify, prioritize, and measure value from automation opportunities, including RPA and related automation efforts.
  • Strong leadership, coaching, collaboration, planning, problem-solving, and decision-making skills.
  • Ability to analyze and present technical documentation, business requirements, financial information, and recommendations to business partners, technology leaders, vendors, and senior management.

Personal Attributes

  • Strong customer-service orientation with the ability to communicate technical concepts in clear, user-friendly language.
  • Excellent written, verbal, listening, and interpersonal communication skills.
  • Self-motivated, detail-oriented, and able to prioritize work effectively in a high-pressure environment.
  • Collaborative team orientation with the ability to research, assess, and resolve application, integration, and technology issues.

Supervisory Responsibilities

Carries out supervisory responsibilities in accordance with the organization’s policies and applicable laws. Responsibilities include interviewing, hiring, and training employees; planning, assigning, and directing work; appraising performance; recognizing and disciplining employees; addressing concerns; resolving problems; and supporting employee development and engagement.

A minimum requirement for this position is the ability to work legally in the United States. No visa sponsorship/support is available for this position, including for any type of U.S. permanent residency (green card) process.

SOURCE:

LINKEDIN/OTLK

reddit.com
u/pfelgueiras — 1 month ago
▲ 9 r/OTLK_Investors

CENCORA STRATEGIC INVESTMENTS IN RETINA DONE

Cencora’s strategic investments in retina are worth paying attention to:

• Retina Consultants of America (RCA): ~$4.6B

→ $4.4B cash at closing for ~85% of RCA, with up to $500M in additional earn-out payments.

→ Nearly 300 retina specialists across 23 states.

• EyeSouth Partners – Retina business: $1.1B

→ Cencora is integrating the retina physicians into RCA, further expanding its U.S. retina network.

That’s $5.5B+ committed to building a major retina platform.

And Cencora already has a strategic commercialization/distribution relationship with OTLK / LYTENAVA.

A full acquisition of OTLK would therefore make strategic sense:

Cencora would have the retina network + commercial infrastructure + an FDA-approved ophthalmic anti-VEGF product under one roof.

Not saying an acquisition is coming, but strategically, the pieces fit.

SOURCE:

Stocktwits/OTLK/Tom2772

u/pfelgueiras — 1 month ago